From the above studies, it is reasonable to speculate that the circadian clock may be related to increased de novo fatty acid synthesis in tumors, and tumor-dependent metabolites may be secreted in a temporal manner, which indicates that targeted pharmacological studies can be conducted on the daily peak of fatty acid metabolism pathway. The gene discussed is CLOCK; the disease is neoplasm.